A new study found that a diabetes drug may also be a promising treatment for obesity. A large trial conducted on this found that people taking the drug lost 15% of their body weight. This is more than that has been seen with any other obesity drugs available on the market. Semaglutide is an injectable medication for diabetes and is approved to help control blood sugar levels in people with Type 2 diabetes. Now the studies and trials have found that the drug not only cures diabetes but also suppresses appetite. The new study on this drug was published by The New England Journal of Medicine. As a part of the trial, the researchers assigned 1,961 obese or overweight adults to receive semaglutide or placebo once a week for 68 weeks.
The counseling sessions are done once a month also helped them to follow a reduced-calorie diet and they were encouraged to increase the physical activity also. By the end of the 68th week, it found that those who received semaglutide lost 14.9% of their body weight, on average, compared with just 2.4% of body weight in the placebo group. Also, the weight loss drug phentermine is given to a group of people and is not effective as semaglutide.
But people who consumed semaglutide were more likely to experience side effects such as nausea, diarrhea, vomiting, and constipation. Researchers say that these side effects are found temporary. According to Carbofix reviews, the research did not look at the drug’s effects beyond 68 weeks and people would likely need to stay on the injection for their whole life to prevent reversing the results.
Five drugs that treat obesity can typically be used for only short periods of time
Five other drugs are also approved to treat obesity. But the most effective drug among them results in about 7.5% weight loss. Researchers say that this can typically be used for only short periods of time. Dr. Robert F. Kushner, the man who led the study and an obesity researcher at Northwestern University Feinberg School of Medicine, said, “This is the start of a new era of effective treatments for obesity”.
The makers of semaglutide, Novo Nordisk, funded the studies and The Danish pharmaceutical company has already submitted an application with the FDA for approval of semaglutide for chronic weight management options like Biofit.
Around 86.4% of adults were able to cut at least 5% of their baseline body weight while only 31.5% of those adhering to lifestyle intervention only. Almost, 70% of those on semaglutide plus lifestyle intervention achieved a 10% or more weight loss and more than half were able to lose 15% of their baseline body weight.
Results of the first 4 weeks of treatment initiation, those on semaglutide had more than a 2% reduction in body weight and continued to lose weight throughout the 68-week trial. Kushner said that “I was surprised and gratified to see the unprecedented results from the medication. The fact that 50% of participants were able to lose at least 15% of initial body weight and one-third lost at least 20% body weight is a game-changer. Semaglutide is by far the most effective drug intervention we have seen for weight management. We now need to explore how to encourage and educate healthcare providers to provide obesity care in the primary care setting.”
“We know that a lot of the health concerns we see in people who struggle with their weight, such as type 2 diabetes, hypertension, GERD (gastroesophageal reflux disease), and arthritis of the weight-bearing joints, are improved by losing at least 10% of their body weight. The study conducted and published by The New England Journal for Medicine found that nearly 70% of participants were able to achieve this 10% weight loss threshold by taking semaglutide injection.